Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for hard numbers on Microbot Medical’s cash runway or the latest patent additions behind its LIBERTY micro-robotic platform? Investors typically start with the 10-K annual report, but wading through hundreds of pages of R&D tables can be time–consuming. Our SEC filings hub anticipates that journey and answers the common search, “Microbot Medical SEC filings explained simply,” with clear context for every document.
The moment a Microbot Medical quarterly earnings report 10-Q filing or an 8-K material event posts to EDGAR, Stock Titan delivers real-time access plus AI-powered summaries that translate clinical trial jargon into plain language. Need to monitor executive moves? Track every Microbot Medical insider trading Form 4 transactions notice alongside Microbot Medical Form 4 insider transactions real-time alerts so you never miss a buy or sell.
- See R&D expense trends with “Microbot Medical earnings report filing analysis.”
- Review patent milestones and regulatory disclosures through “Microbot Medical 8-K material events explained.”
- Compare leadership pay packages inside the “Microbot Medical proxy statement executive compensation.”
Each filing page pairs the original PDF with an easy-to-scan AI digest—ideal for understanding Microbot Medical SEC documents with AI when minutes matter. Whether you’re deciphering a Microbot Medical annual report 10-K simplified section on intellectual property or spotting patterns in a Microbot Medical executive stock transactions Form 4, our platform connects the dots, surfaces key figures, and updates automatically. Stop searching multiple sources; everything you need is organized in one place, refreshed the instant Microbot Medical submits a new disclosure.
Microbot Medical Inc. (MBOT) filed a preliminary S-3 registering up to 900,153 shares of common stock for resale by selling stockholders. The shares may be issued upon exercise of outstanding preferred investment options held by those stockholders. The company is not selling shares in this offering and will not receive proceeds from any resales.
Microbot may receive up to approximately $2.1 million in gross proceeds only if all registered options are exercised for cash; some options allow cashless exercise. The plan of distribution permits multiple methods, including short sales after the registration statement is declared effective. Examples include Noam Rubenstein 283,548 and Michael Vasinkevich 577,223 from the selling stockholder table. Shares outstanding were 67,158,044 as of October 10, 2025. MBOT last closed at $2.92 on October 10, 2025.
Microbot Medical Inc. filed a Form D reporting a completed Regulation D private offering under Rule 506(b). The issuer raised aggregate proceeds of $25,244,903, of which $25,244,903 has been sold and $0 remains. The filing states the total offering amount reflects the aggregate exercise price of inducement preferred investment options and placement-agent preferred investment options. The placement agent received cash fees totaling $2,095,542 and was also granted 1,342,694 preferred investment options exercisable for common stock at prices ranging from $1.875 to $2.6625. The offering was a new notice with a first sale date of 2025-09-16, claimed a minimum investment of $0, and was not part of a business combination. The Form D was signed by CFO Rachel Vaknin on 2025-09-29.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
